^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CEACAM1 overexpression

    i
    Other names: CEACAM1, CEA Cell Adhesion Molecule 1, BGP1, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein), Carcinoembryonic Antigen Related Cell Adhesion Molecule 1, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1, CD66a Antigen, BGP, Biliary Glycoprotein 1, Antigen CD66, CEACAM1, CD66a, BGP-1, BGPI
    Entrez ID:
    634
    1year
    CEACAM expression in an in-vitro prostatitis model. (PubMed, Front Immunol)
    Furthermore, overexpressed CEACAM1-L is associated with the deregulated expression of JAK/STAT, NFκB, and epithelial-mesenchymal transition (EMT) genes, as well as an increased cell migration. We postulate that CEACAM1 isoform CEACAM1-4L may synergistically contribute to inflammation-induced oncogenesis in the prostate.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    CEACAM1 overexpression
    4years
    [VIRTUAL] Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients (SITC 2020)
    Moreover, MG1124 showed synergistic anti-cancer activity with pembrolizumab in NSCLC huPDX models...The data presented herein support further advancement of MG1124 towards clinical development. MG1124 is a potential therapeutic candidate for immune checkpoint blockade in cancer therapy.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IL2 (Interleukin 2) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    CEACAM1 overexpression
    |
    Keytruda (pembrolizumab)
    4years
    [VIRTUAL] Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients (SITC 2020)
    Moreover, MG1124 showed synergistic anti-cancer activity with pembrolizumab in NSCLC huPDX models...The data presented herein support further advancement of MG1124 towards clinical development. MG1124 is a potential therapeutic candidate for immune checkpoint blockade in cancer therapy.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IL2 (Interleukin 2) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    CEACAM1 overexpression
    |
    Keytruda (pembrolizumab)